FDA grants priority review for full approval of TARPEYO for the treatment of IgA Nephropathy August 18, 2023 10:00 CET Regulatory Read more
Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ) May 30, 2023 16:00 CET Regulatory Read more
Notice of annual general meeting of Calliditas Therapeutics AB (publ) April 28, 2023 08:30 CET Regulatory Read more
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy March 12, 2023 18:30 CET Regulatory Read more
Number of shares and votes in Calliditas Therapeutics January 31, 2023 08:00 CET Regulatory Read more
